ID30225A - Tablet matriks yang memungkinkan pelepasan yang diperlama dari gliklazida setelah pemberian secara oral - Google Patents

Tablet matriks yang memungkinkan pelepasan yang diperlama dari gliklazida setelah pemberian secara oral

Info

Publication number
ID30225A
ID30225A IDW00200101671A ID20011671A ID30225A ID 30225 A ID30225 A ID 30225A ID W00200101671 A IDW00200101671 A ID W00200101671A ID 20011671 A ID20011671 A ID 20011671A ID 30225 A ID30225 A ID 30225A
Authority
ID
Indonesia
Prior art keywords
extension
gliclazide
allows
tablet matrix
oral giving
Prior art date
Application number
IDW00200101671A
Other languages
English (en)
Indonesian (id)
Inventor
Bruno Huet De Barochez
Patrick Wuthrich
Louis Martin
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9541429&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ID30225(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Adir filed Critical Adir
Publication of ID30225A publication Critical patent/ID30225A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW00200101671A 1999-02-01 1999-10-15 Tablet matriks yang memungkinkan pelepasan yang diperlama dari gliklazida setelah pemberian secara oral ID30225A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9901082A FR2788981B1 (fr) 1999-02-01 1999-02-01 Comprime matriciel permettant la liberation prolongee de gliclazide apres administration par voie orale

Publications (1)

Publication Number Publication Date
ID30225A true ID30225A (id) 2001-11-15

Family

ID=9541429

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW00200101671A ID30225A (id) 1999-02-01 1999-10-15 Tablet matriks yang memungkinkan pelepasan yang diperlama dari gliklazida setelah pemberian secara oral

Country Status (36)

Country Link
US (1) US6733782B1 (de)
EP (1) EP1148871B1 (de)
JP (2) JP4716465B2 (de)
KR (1) KR100491600B1 (de)
CN (1) CN1160061C (de)
AP (1) AP1243A (de)
AT (1) ATE296621T1 (de)
AU (1) AU764516B2 (de)
BR (1) BR9917012A (de)
CA (1) CA2273420C (de)
CZ (1) CZ298196B6 (de)
DE (1) DE69925639T2 (de)
DK (1) DK1148871T3 (de)
EA (1) EA002625B1 (de)
EE (1) EE05024B1 (de)
ES (1) ES2241323T3 (de)
FR (1) FR2788981B1 (de)
GE (1) GEP20053501B (de)
HR (1) HRP20010632B1 (de)
HU (1) HU225693B1 (de)
ID (1) ID30225A (de)
IL (2) IL144246A0 (de)
ME (1) ME00436B (de)
NO (1) NO329951B1 (de)
NZ (1) NZ512878A (de)
OA (1) OA11756A (de)
PL (1) PL194505B1 (de)
PT (1) PT1148871E (de)
RS (1) RS50121B (de)
SA (1) SA00210446B1 (de)
SK (1) SK285209B6 (de)
TR (1) TR200102002T2 (de)
UA (1) UA68414C2 (de)
WO (1) WO2000018373A1 (de)
YU (1) YU53101A (de)
ZA (1) ZA200106305B (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
SE0200539D0 (sv) * 2002-02-25 2002-02-25 Metcon Medicin Ab Granulation process and starch granulate
CN100391459C (zh) * 2003-05-26 2008-06-04 沈阳药科大学 甲磺酸多沙唑嗪缓释制剂
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
RU2359677C2 (ru) * 2004-04-29 2009-06-27 Лотус Фармасьютикал Ко., Лтд Оральные таблетки с модифицированным высвобождением и способ их получения
CN100413491C (zh) * 2004-06-14 2008-08-27 北京德众万全药物技术开发有限公司 一种难溶性药物的控释制剂
RU2273482C2 (ru) * 2004-06-21 2006-04-10 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Фармацевтическая композиция с пролонгированным высвобождением гликлазида
EP1827453A1 (de) * 2004-12-06 2007-09-05 Themis Laboratories Private Limited Sulfonylharnstoff-zusammensetzungen und verfahren zu ihrer herstellung
WO2007055329A1 (ja) * 2005-11-11 2007-05-18 Asahi Kasei Chemicals Corporation 徐放性固形製剤
US20080286343A1 (en) * 2007-05-16 2008-11-20 Dzenana Cengic Solid form
TR200704897A1 (tr) * 2007-07-13 2009-02-23 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Uzatılmış salım sağlayan gliklazid formülasyonları@
TR200708938A2 (tr) * 2007-12-26 2008-11-21 Ali̇ Rai̇f İlaç Sanayi̇ Ve Ti̇caret A.Ş. Uzatılmış salım sağlayan gliklazid tablet
ITFI20080016A1 (it) * 2008-02-05 2009-08-06 Valpharma Sa Formulazioni farmaceutiche orali contenenti gliclazide.
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
WO2009140279A2 (en) * 2008-05-12 2009-11-19 Concert Pharmaceuticals, Inc. Sulfonyl urea compounds
EP2181705A1 (de) 2008-10-31 2010-05-05 Disphar International B.V. Gliclazid-Formulierung mit verlängerter Freisetzung
US10071068B2 (en) * 2009-03-03 2018-09-11 Xenoport, Inc. Sustained release oral dosage forms of an R-baclofen prodrug
UY33455A (es) 2010-06-16 2012-01-31 Teijin Pharma Ltd Tableta con núcleo recubierto de liberación controlada
TR201107482A1 (tr) 2010-12-21 2012-07-23 Sanovel İlaç San.Ve Ti̇c.A.Ş. Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu.
EP2468268B1 (de) 2010-12-21 2017-12-13 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Kombinationszusammensetzung aus Vildagliptin und Gliclazid
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
CA2865484A1 (en) 2012-02-24 2013-08-29 Ranbaxy Laboratories Limited Stabilized controlled-release pharmaceutical composition comprising gliclazide
EP2958548A1 (de) 2013-02-19 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Verfahren zur herstellung von gliclazid-formulierungen
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
ITMI20132065A1 (it) * 2013-12-11 2015-06-12 Farmatron Ltd Sistemi terapeutici a rilascio modificato per la somministrazione orale di curcumina nel trattamento delle malattie intestinali
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
WO2016042568A1 (en) * 2014-09-16 2016-03-24 Suresh Pareek Extended release formulation of gliclazide
CN111329841B (zh) * 2020-03-04 2021-11-19 山东鲁抗医药集团赛特有限责任公司 格列齐特缓释片及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1449404A (en) * 1973-03-30 1976-09-15 Science Union & Cie N-arylsulphonyl urea derivatives
US4056623A (en) * 1975-03-05 1977-11-01 Science Union Et Cie, Societe Francaise De Recherche Medicale Methods of treating animals suffering from hyperlipidemia using certain N-phenyl sulphonyl-N'-(3-azabicycloalkyl) ureas
US5057321A (en) * 1990-06-13 1991-10-15 Alza Corporation Dosage form comprising drug and maltodextrin
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
DE4336159A1 (de) * 1993-10-22 1995-04-27 Kurt Heinz Prof Dr Bauer Hochwirksame, den Wirkstoff schnell oder kontrolliert freisetzende Zubereitungsformen von Sulfonylharnstoffen und Verfahren zu deren Herstellung
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.

Also Published As

Publication number Publication date
AP1243A (en) 2004-02-02
ZA200106305B (en) 2002-07-31
AU764516B2 (en) 2003-08-21
FR2788981A1 (fr) 2000-08-04
CN1160061C (zh) 2004-08-04
DE69925639D1 (de) 2005-07-07
EP1148871A1 (de) 2001-10-31
PT1148871E (pt) 2005-08-31
HRP20010632A2 (en) 2005-02-28
EA200100827A1 (ru) 2002-02-28
OA11756A (en) 2005-07-19
IL144246A0 (en) 2002-05-23
CA2273420A1 (fr) 2000-08-01
IL144246A (en) 2006-12-10
CZ20012661A3 (cs) 2001-11-14
FR2788981B1 (fr) 2002-05-17
US6733782B1 (en) 2004-05-11
RS50121B (sr) 2009-03-25
EE200100398A (et) 2002-10-15
HUP0105365A2 (hu) 2002-04-29
AP2001002212A0 (en) 2001-09-30
JP4716465B2 (ja) 2011-07-06
ATE296621T1 (de) 2005-06-15
CA2273420C (fr) 2002-07-09
KR100491600B1 (ko) 2005-05-27
YU53101A (sh) 2004-05-12
EE05024B1 (et) 2008-06-16
NZ512878A (en) 2002-05-31
JP2002525310A (ja) 2002-08-13
PL356707A1 (en) 2004-06-28
TR200102002T2 (tr) 2002-01-21
NO20013757L (no) 2001-08-09
SK285209B6 (sk) 2006-08-03
GEP20053501B (en) 2005-05-10
BR9917012A (pt) 2002-04-16
ME00436B (me) 2011-10-10
DK1148871T3 (da) 2005-09-19
HRP20010632B1 (en) 2006-02-28
AU6098299A (en) 2000-04-17
ES2241323T3 (es) 2005-10-16
KR20010093307A (ko) 2001-10-27
DE69925639T2 (de) 2006-04-27
NO329951B1 (no) 2011-01-31
EA002625B1 (ru) 2002-06-27
SK10952001A3 (sk) 2001-12-03
NO20013757D0 (no) 2001-07-31
CN1342068A (zh) 2002-03-27
EP1148871B1 (de) 2005-06-01
WO2000018373A1 (fr) 2000-04-06
SA00210446B1 (ar) 2006-10-11
JP2008179649A (ja) 2008-08-07
HK1043049A1 (en) 2002-09-06
CZ298196B6 (cs) 2007-07-18
HUP0105365A3 (en) 2002-11-28
UA68414C2 (en) 2004-08-16
HU225693B1 (en) 2007-06-28
PL194505B1 (pl) 2007-06-29

Similar Documents

Publication Publication Date Title
PT1362582E (pt) Forma de dosagem sólida revestida
ATE456368T1 (de) Reboxetin enthaltende tablette mit verzögerter wirkstoffabgabe
ID26334A (id) Morfolinol yang aktif secara farmasi
FI991485L (fi) Uusi farmaseuttinen koostumus
NO20011085D0 (no) Tablett med umiddelbar frigivningsvirkning
NO20015175L (no) Farmasöytisk sammensetning
EE200100398A (et) Suu kaudu manustatud gliklasiidi kestusvabanemistvõimaldav maatrikstablett
CY2007031I1 (el) Συνθεση στοματικης δοσολογιας παρατεταμενης απελευθερωσης
IS5541A (is) Áfangatöflur til inntöku
DE60034307D1 (de) Kombinierte kamera
NO20052335D0 (no) Dispergerbare defracirox-tabletter
IS7571A (is) Ný lífeðlisfræðilega virk efni
ID22233A (id) Tablet telan yang terdiri dari parasetamol
ATE388693T1 (de) Wohlschmeckende kautablette
IS7929A (is) Lyf á föstu formi til inntöku um munn
NO20022645L (no) Farmasöytisk superdisintegrerende stoff
HUP0500004A3 (en) Extended release pharmaceutical tablet of metformin
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
PL368342A1 (en) Chewable tablet containing lysine
FR2802423B1 (fr) Compositions pharmaceutiques
DE60225686D1 (de) Paracetamol enthaltende tablette
DE60232445D1 (de) Cetirizin und pseudoephedrin enthaltende tablette
FI4488U1 (fi) Farmaseuttinen koostumus
AU2003284942A8 (en) Oral extended release tablets and methods of making and using the same